The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

JR, Arribas; A, Horban; J, Gerstoft; G, Fätkenheuer; M, Nelson; N, Clumeck; F, Pulido; A, Hill; Delft Y, van; T, Stark; C, Moecklinghoff

doi:10.1097/qad.0b013e3283348944

Public

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Shared by NobleBlocks on Jan 1, 2010 • 12:00 AM UTC

Authors:

Arribas JR

Horban A

Gerstoft J

Abstract

<h4>Background</h4>In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.<h4>Methods</h4>Two hundred and fifty-six patients with HIV RNA less than 50 copies/ml for over 24 weeks on current antiretro...

Discussions